Stroke associated with discontinuation of warfarin therapy for atrial fibrillation

Christina Spivey, Xianchen Liu, Yanru Qiao, Jack Mardekian, Robert Parker, Hemant Phatak, Cristina Masseria, Sumesh Kachroo, Younos Abdulsattar, Junling Wang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective:The objective of this study was to determine the association between warfarin discontinuation and stroke among patients with nonvalvular atrial fibrillation (NVAF).Research design and methods:This was a retrospective, observational study of adult NVAF patients (≥18 years) who were on warfarin in the Truven MarketScan commercial claims and encounters and Medicare supplemental and coordination of benefits databases (1 January 2008 to 30 June 2012). Warfarin discontinuation was defined as a gap of ≥45 days in warfarin prescription within 1 year after initiation. Patients who did and did not discontinue warfarin were matched at a 1:1 ratio using a propensity score method. Matched patients were followed for up to 1 year to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemorrhagic stroke. A multivariate Cox proportional hazards model was used to further adjust for the effects of potential confounders.Results:A total of 27,000 patients were included. Patients who discontinued warfarin had higher rates of ischemic stroke compared to persistent patients (1.0 vs. 0.5 per 100 patient years, P < 0.01), but similar rates of TIA (1.2 vs. 0.9 per 100 patient years, respectively; P = 0.07) and hemorrhagic stroke (0.3 vs. 0.2 per 100 patient years, P = 0.31). After adjustment for potential confounders, warfarin discontinuation was significantly associated with increased risk of ischemic stroke (hazard ratio [HR]: 2.04; 95% confidence interval [CI]: 1.47-2.84), TIA (HR: 1.36; 95% CI: 1.04-1.78), and ischemic stroke or TIA (HR: 1.50; 95% CI: 1.20-1.87).Conclusions:Warfarin discontinuation is associated with increased risk of ischemic stroke and TIA. Health care providers may need to take a more active role in the management of warfarin discontinuation and clinical outcomes, e.g., by considering newer anticoagulants with favorable risk-benefit profiles. Key limitations of the study include unavailability of important clinical factors and measures in claims data.

Original languageEnglish (US)
Pages (from-to)2021-2029
Number of pages9
JournalCurrent Medical Research and Opinion
Volume31
Issue number11
DOIs
StatePublished - Nov 2 2015
Externally publishedYes

Fingerprint

Warfarin
Atrial Fibrillation
Stroke
Transient Ischemic Attack
Therapeutics
Confidence Intervals
Propensity Score
Medicare
Proportional Hazards Models
Health Personnel
Anticoagulants
Observational Studies
Prescriptions
Research Design
Retrospective Studies
Databases

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. / Spivey, Christina; Liu, Xianchen; Qiao, Yanru; Mardekian, Jack; Parker, Robert; Phatak, Hemant; Masseria, Cristina; Kachroo, Sumesh; Abdulsattar, Younos; Wang, Junling.

In: Current Medical Research and Opinion, Vol. 31, No. 11, 02.11.2015, p. 2021-2029.

Research output: Contribution to journalArticle

Spivey, Christina ; Liu, Xianchen ; Qiao, Yanru ; Mardekian, Jack ; Parker, Robert ; Phatak, Hemant ; Masseria, Cristina ; Kachroo, Sumesh ; Abdulsattar, Younos ; Wang, Junling. / Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. In: Current Medical Research and Opinion. 2015 ; Vol. 31, No. 11. pp. 2021-2029.
@article{a08e396ee90849faa81e3738969bebf6,
title = "Stroke associated with discontinuation of warfarin therapy for atrial fibrillation",
abstract = "Objective:The objective of this study was to determine the association between warfarin discontinuation and stroke among patients with nonvalvular atrial fibrillation (NVAF).Research design and methods:This was a retrospective, observational study of adult NVAF patients (≥18 years) who were on warfarin in the Truven MarketScan commercial claims and encounters and Medicare supplemental and coordination of benefits databases (1 January 2008 to 30 June 2012). Warfarin discontinuation was defined as a gap of ≥45 days in warfarin prescription within 1 year after initiation. Patients who did and did not discontinue warfarin were matched at a 1:1 ratio using a propensity score method. Matched patients were followed for up to 1 year to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemorrhagic stroke. A multivariate Cox proportional hazards model was used to further adjust for the effects of potential confounders.Results:A total of 27,000 patients were included. Patients who discontinued warfarin had higher rates of ischemic stroke compared to persistent patients (1.0 vs. 0.5 per 100 patient years, P < 0.01), but similar rates of TIA (1.2 vs. 0.9 per 100 patient years, respectively; P = 0.07) and hemorrhagic stroke (0.3 vs. 0.2 per 100 patient years, P = 0.31). After adjustment for potential confounders, warfarin discontinuation was significantly associated with increased risk of ischemic stroke (hazard ratio [HR]: 2.04; 95{\%} confidence interval [CI]: 1.47-2.84), TIA (HR: 1.36; 95{\%} CI: 1.04-1.78), and ischemic stroke or TIA (HR: 1.50; 95{\%} CI: 1.20-1.87).Conclusions:Warfarin discontinuation is associated with increased risk of ischemic stroke and TIA. Health care providers may need to take a more active role in the management of warfarin discontinuation and clinical outcomes, e.g., by considering newer anticoagulants with favorable risk-benefit profiles. Key limitations of the study include unavailability of important clinical factors and measures in claims data.",
author = "Christina Spivey and Xianchen Liu and Yanru Qiao and Jack Mardekian and Robert Parker and Hemant Phatak and Cristina Masseria and Sumesh Kachroo and Younos Abdulsattar and Junling Wang",
year = "2015",
month = "11",
day = "2",
doi = "10.1185/03007995.2015.1082995",
language = "English (US)",
volume = "31",
pages = "2021--2029",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Stroke associated with discontinuation of warfarin therapy for atrial fibrillation

AU - Spivey, Christina

AU - Liu, Xianchen

AU - Qiao, Yanru

AU - Mardekian, Jack

AU - Parker, Robert

AU - Phatak, Hemant

AU - Masseria, Cristina

AU - Kachroo, Sumesh

AU - Abdulsattar, Younos

AU - Wang, Junling

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Objective:The objective of this study was to determine the association between warfarin discontinuation and stroke among patients with nonvalvular atrial fibrillation (NVAF).Research design and methods:This was a retrospective, observational study of adult NVAF patients (≥18 years) who were on warfarin in the Truven MarketScan commercial claims and encounters and Medicare supplemental and coordination of benefits databases (1 January 2008 to 30 June 2012). Warfarin discontinuation was defined as a gap of ≥45 days in warfarin prescription within 1 year after initiation. Patients who did and did not discontinue warfarin were matched at a 1:1 ratio using a propensity score method. Matched patients were followed for up to 1 year to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemorrhagic stroke. A multivariate Cox proportional hazards model was used to further adjust for the effects of potential confounders.Results:A total of 27,000 patients were included. Patients who discontinued warfarin had higher rates of ischemic stroke compared to persistent patients (1.0 vs. 0.5 per 100 patient years, P < 0.01), but similar rates of TIA (1.2 vs. 0.9 per 100 patient years, respectively; P = 0.07) and hemorrhagic stroke (0.3 vs. 0.2 per 100 patient years, P = 0.31). After adjustment for potential confounders, warfarin discontinuation was significantly associated with increased risk of ischemic stroke (hazard ratio [HR]: 2.04; 95% confidence interval [CI]: 1.47-2.84), TIA (HR: 1.36; 95% CI: 1.04-1.78), and ischemic stroke or TIA (HR: 1.50; 95% CI: 1.20-1.87).Conclusions:Warfarin discontinuation is associated with increased risk of ischemic stroke and TIA. Health care providers may need to take a more active role in the management of warfarin discontinuation and clinical outcomes, e.g., by considering newer anticoagulants with favorable risk-benefit profiles. Key limitations of the study include unavailability of important clinical factors and measures in claims data.

AB - Objective:The objective of this study was to determine the association between warfarin discontinuation and stroke among patients with nonvalvular atrial fibrillation (NVAF).Research design and methods:This was a retrospective, observational study of adult NVAF patients (≥18 years) who were on warfarin in the Truven MarketScan commercial claims and encounters and Medicare supplemental and coordination of benefits databases (1 January 2008 to 30 June 2012). Warfarin discontinuation was defined as a gap of ≥45 days in warfarin prescription within 1 year after initiation. Patients who did and did not discontinue warfarin were matched at a 1:1 ratio using a propensity score method. Matched patients were followed for up to 1 year to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemorrhagic stroke. A multivariate Cox proportional hazards model was used to further adjust for the effects of potential confounders.Results:A total of 27,000 patients were included. Patients who discontinued warfarin had higher rates of ischemic stroke compared to persistent patients (1.0 vs. 0.5 per 100 patient years, P < 0.01), but similar rates of TIA (1.2 vs. 0.9 per 100 patient years, respectively; P = 0.07) and hemorrhagic stroke (0.3 vs. 0.2 per 100 patient years, P = 0.31). After adjustment for potential confounders, warfarin discontinuation was significantly associated with increased risk of ischemic stroke (hazard ratio [HR]: 2.04; 95% confidence interval [CI]: 1.47-2.84), TIA (HR: 1.36; 95% CI: 1.04-1.78), and ischemic stroke or TIA (HR: 1.50; 95% CI: 1.20-1.87).Conclusions:Warfarin discontinuation is associated with increased risk of ischemic stroke and TIA. Health care providers may need to take a more active role in the management of warfarin discontinuation and clinical outcomes, e.g., by considering newer anticoagulants with favorable risk-benefit profiles. Key limitations of the study include unavailability of important clinical factors and measures in claims data.

UR - http://www.scopus.com/inward/record.url?scp=84947492471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947492471&partnerID=8YFLogxK

U2 - 10.1185/03007995.2015.1082995

DO - 10.1185/03007995.2015.1082995

M3 - Article

VL - 31

SP - 2021

EP - 2029

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 11

ER -